Pharmaron Raises $40 Million to Expand CRO Operations

Pharmaron Holding Limited, a Beijing CRO, closed a Series C financing round totaling over $40 million. Pharmaron will use the new capital to strengthen and expand its drug discovery services offerings, preclinical GLP toxicology capabilities and GMP chemical synthesis services. Pharmaron has five preclinical facilities in Beijing, with a GMP Pilot Plant currently under construction. More details....